ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1313

Tolerance of Rituximab in Patients with a History of Cancer : Data From the Registry Air

Jacques-Eric Gottenberg1, Marie-Odile Duzanski2, Thomas Bardin3, Patrice Cacoub4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Eric Hachulla11, Xavier Le Loet12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Philippe Ravaud16, Gabriel Baron17 and Xavier Mariette18, 1Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 3Rheumatology, Hôpital Lariboisière, Paris, France, 4Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, 6Rheumatology, Hopital Lapeyronie, Montpellier, France, 7Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 8Rheumatology, Hopital R Salengro CHRU, Lille, France, 9Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 10Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 11Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 12Rheumatology Department, CHU de ROUEN, Rouen, France, 13Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 14Rheumatology, CHU Hautepierre, Strasbourg, France, 15Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 16Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 17Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, 18Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cancer treatments and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Data regarding tolerance of biologics in patients with a history of cancer are very limited.

We therefore analyzed tolerance of rituximab (RTX) in patients with a history of cancer

included in the AIR (“Autoimmunity and Rituximab”) registry.

Methods: The French Society of Rheumatology has set up a nationwide prospective 7-year registry, AIR to investigate the long-term safety and efficacy in real life of RTX.

Results:

Among the 2000 patients enrolled, 272 patients (13.6%) treated with RTX had a history of cancer prior to RTX. 33% of them had a history of breast cancer with a median duration of  6 years, 15% of skin cancer (6% melanoma ), 14% of lymphoma, 7% a prostate cancer, 6% an uterus cancer, 5% a colorectal cancer, 3% a thyroid cancer and 17% another cancer (kidney, bladder, lung, blood malignancies,  brain). The main baseline characteristics of these patients (disease duration 15 years, record of serious or recurrent infections: 35.2%, proportion of patients treated without a concomitant synthetic DMARD:38.2%) were comparable to those of patients without a history of cancer, except an older age (63 vs 58 years), a higher proportion of patients without anti-TNF prior to RTX (55% vs 83%) and a lower disease activity (median DAS28: 5.2 vs 5.6). The median time between the diagnosis of cancer and the first infusion was 4 [0-46] years. 270 patients with a history of cancer had at least 1 follow-up visit respectively, with a median follow-up period of 2.8 years (756 patient/years) and 1709 patients without a history of cancer had a follow-up visit with a median follow-up of 2.8 years  (4785 patient/years).

–Cancers : Among the patients with a history of cancer, 20 patients had a recurrence of cancer or a second cancer (2.6 cancers /100 patient/years). 13 (5%, 1.7/100 patient/years) developed metastases or recurrence of their previous cancer (breast:3, colon: 1, liver; 2, lung:2, myeloma:1, skin:1, uterus:1, bladder:1, kidney: 1) and 7 (2.6%, 0.9 cancer/100 PY).)developed a new cancer (skin:3, bladder:2, colon: 1,  pancreas:1).. Among the patients without a history of cancer, 43 cancers (0.9 cancer/100 patient/years) (skin: 10, breast: 6, lung: 5, prostate: 4, others: 18) occurred after a median duration of 22 months after the 1st RTX infusion.

– Serious infections :25 and 214 patients with/without history of cancer had a serious infection (3.3 and 4.5 serious infections /100 patient/years, respectively).

– Deaths :15 and 64 patients with/without history of cancer died (1.9 and 1.3 deaths /100 patient/years, respectively).

Conclusion:

RTX is often used in common practice in patients with history of cancer, although data are limited except for lymphomas. After nearly 3 years of follow-up, overall safety of RTX seems comparable in patients with or without history of cancer. The risk of a new cancer is the same than in patients without any previous cancer. The risk of cancer recurrence is difficult to evaluate in the absence of a control group of RA patients with cancers of matched histology, severity and duration, non-treated with RTX. Collaboration between registries might help to address this issue.


Disclosure:

J. E. Gottenberg,
None;

M. O. Duzanski,
None;

T. Bardin,
None;

P. Cacoub,
None;

A. G. Cantagrel,
None;

B. Combe,
None;

M. Dougados,
None;

R. M. Flipo,
None;

B. Godeau,
None;

L. Guillevin,
None;

E. Hachulla,
None;

X. Le Loet,
None;

T. Schaeverbeke,
None;

J. Sibilia,
None;

I. Pane,
None;

P. Ravaud,
None;

G. Baron,
None;

X. Mariette,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tolerance-of-rituximab-in-patients-with-a-history-of-cancer-data-from-the-registry-air/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology